Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 1/2 19Phase 1 14Phase NA 8Phase 3 6Phase 2/3 4Phase EARLY_PHASE1 1

Status

Recruiting 6Completed 6Active not recruiting 5Not yet recruiting 3Terminated 2Unknown 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Gemcitabine 5Cisplatin 5durvalumab 3zanidatamab 2Trastuzumab 2trastuzumab deruxtecan 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1encorafenib 1binimetinib 1Oxaliplatin 1Leucovorin 1Irinotecan 1Folfox protocol 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Biliary Tract Neoplasms × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

AstraZeneca

Phase 3 Recruiting
620 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT07062263 2025-07-14

TAB-2

Tata Memorial Centre

Phase 3 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡